HUE060376T2 - Ccr2 modulátorok - Google Patents
Ccr2 modulátorokInfo
- Publication number
- HUE060376T2 HUE060376T2 HUE16797279A HUE16797279A HUE060376T2 HU E060376 T2 HUE060376 T2 HU E060376T2 HU E16797279 A HUE16797279 A HU E16797279A HU E16797279 A HUE16797279 A HU E16797279A HU E060376 T2 HUE060376 T2 HU E060376T2
- Authority
- HU
- Hungary
- Prior art keywords
- ccr2 modulators
- ccr2
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562164957P | 2015-05-21 | 2015-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE060376T2 true HUE060376T2 (hu) | 2023-02-28 |
Family
ID=57320660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE16797279A HUE060376T2 (hu) | 2015-05-21 | 2016-05-19 | Ccr2 modulátorok |
Country Status (27)
Country | Link |
---|---|
US (4) | US9783540B2 (hu) |
EP (1) | EP3297438B1 (hu) |
JP (1) | JP6841771B2 (hu) |
KR (1) | KR102622891B1 (hu) |
CN (1) | CN108135168B (hu) |
AR (1) | AR104720A1 (hu) |
AU (1) | AU2016263579B2 (hu) |
BR (1) | BR112017024555A2 (hu) |
CA (1) | CA2985194A1 (hu) |
CY (1) | CY1124918T1 (hu) |
DK (1) | DK3297438T3 (hu) |
ES (1) | ES2904252T3 (hu) |
HR (1) | HRP20220028T1 (hu) |
HU (1) | HUE060376T2 (hu) |
IL (1) | IL255509B (hu) |
LT (1) | LT3297438T (hu) |
MA (1) | MA42133A (hu) |
MX (1) | MX2017014375A (hu) |
NZ (1) | NZ737399A (hu) |
PL (1) | PL3297438T3 (hu) |
PT (1) | PT3297438T (hu) |
RS (1) | RS62809B1 (hu) |
RU (1) | RU2726206C2 (hu) |
SI (1) | SI3297438T1 (hu) |
TW (1) | TWI733670B (hu) |
WO (1) | WO2016187393A1 (hu) |
ZA (1) | ZA201707966B (hu) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9046025B2 (en) | 2013-06-07 | 2015-06-02 | GM Global Technology Operations LLC | Selective catalytic reduction device monitoring system |
AU2016263579B2 (en) | 2015-05-21 | 2020-12-03 | Chemocentryx, Inc. | CCR2 modulators |
WO2017165125A1 (en) * | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
MX2018013413A (es) | 2016-05-26 | 2019-06-06 | Zeno Royalties & Milestones Llc | Compuestos inhibidores de egfr. |
WO2018237383A1 (en) * | 2017-06-23 | 2018-12-27 | The Trustees Of Columbia University In The City Of New York | METHODS OF PREVENTING AND TREATING DISEASES CHARACTERIZED BY SYNAPTIC DYSFUNCTION AND NEURODEGENERATION, INCLUDING ALZHEIMER'S DISEASE |
CN111712242B (zh) * | 2017-09-25 | 2023-11-24 | 凯莫森特里克斯股份有限公司 | 使用趋化因子受体2(ccr2)拮抗剂和pd-1/pd-l1抑制剂的联合治疗 |
JP2020536919A (ja) | 2017-10-11 | 2020-12-17 | ケモセントリックス, インコーポレイテッド | Ccr2アンタゴニストによる巣状分節性糸球体硬化症の治療 |
WO2019136368A2 (en) * | 2018-01-08 | 2019-07-11 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
JP7263659B2 (ja) * | 2018-02-02 | 2023-04-25 | シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド | カルボン酸基を含む窒素含有ベンゾ複素環化合物、その調製方法及び使用 |
EP3833762A4 (en) | 2018-08-09 | 2022-09-28 | Verseau Therapeutics, Inc. | OLIGONUCLEOTIDE COMPOSITIONS FOR TARGETING CCR2 AND CSF1R AND THEIR USES |
JPWO2020213665A1 (hu) | 2019-04-17 | 2020-10-22 | ||
JP2022539830A (ja) | 2019-07-10 | 2022-09-13 | ケモセントリックス,インコーポレイティド | Pd-l1阻害剤としてのインダン |
CN111139294A (zh) * | 2020-01-06 | 2020-05-12 | 中国药科大学 | Fdps在制备治疗非酒精性脂肪性肝炎药物中的应用 |
MX2022011173A (es) * | 2020-03-10 | 2022-10-18 | Redhill Biopharma Ltd | Tratamiento de infeccion por coronavirus. |
CN111423454B (zh) * | 2020-04-24 | 2021-06-22 | 苏州大学 | 哌嗪类化合物及其在制备趋化因子受体ccr2拮抗剂中的应用 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1296978A2 (en) * | 2000-06-30 | 2003-04-02 | Bristol-Myers Squibb Company | N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity |
AU8334501A (en) | 2000-08-17 | 2002-02-25 | Merck & Co Inc | Cyclopentyl modulators of chemokine receptor activity |
AU2003223755B2 (en) | 2002-04-29 | 2008-08-21 | Merck Sharp & Dohme Corp. | Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity |
US20060030582A1 (en) | 2002-04-29 | 2006-02-09 | Demartino Julie | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
TWI262077B (en) * | 2002-04-29 | 2006-09-21 | Merck & Co Inc | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
NZ536477A (en) * | 2002-04-29 | 2005-05-27 | Merck & Co Inc | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
JP2006508948A (ja) | 2002-10-30 | 2006-03-16 | メルク エンド カムパニー インコーポレーテッド | ケモカイン受容体活性のヘテロアリールピペリジンモジュレーター |
WO2004076411A2 (en) | 2003-02-24 | 2004-09-10 | Merck & Co., Inc. | Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity |
US7553841B2 (en) | 2003-03-18 | 2009-06-30 | Merck & Co., Inc. | Amino cyclobutylamide modulators of chemokine receptor activity |
NZ543287A (en) * | 2003-04-15 | 2008-08-29 | Merck & Co Inc | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors |
AU2004232939A1 (en) | 2003-04-17 | 2004-11-04 | Merck Sharp & Dohme Corp. | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity |
US20060205761A1 (en) | 2003-06-06 | 2006-09-14 | Catherine Abbadie | Ccr-2 antagonists for treatment of neuropathic pain |
AR045875A1 (es) | 2003-10-27 | 2005-11-16 | Merck & Co Inc | Procedimiento para la preparacion del antagonista ccr-2 |
RU2317295C1 (ru) | 2003-10-27 | 2008-02-20 | Мерк Энд Ко., Инк. | Соль антагониста ccr-2 |
EP1701724A4 (en) * | 2004-01-02 | 2007-11-14 | Merck & Co Inc | CYCLOPENTYL AMIDE MODULATORS OF ALKYLAMINO, ARYLAMINO AND SULFONAMIDO OF CHEMOKINE RECEPTOR ACTIVITY |
AU2005214319B2 (en) * | 2004-02-12 | 2009-02-19 | Merck Sharp & Dohme Corp. | Amino heterocyclic modulators of chemokine receptor activity |
GEP20084519B (en) | 2004-05-11 | 2008-10-27 | Incyte Corp | 3-(4-heteroarylcyclo-hexylamino) cyclopenta-necarboxamides as modulators of chemokine receptors |
UY29219A1 (es) | 2004-11-22 | 2006-04-28 | Incyte Corp | Sales de la n-(2- (((3r)-1-(trans-4-hidroxi-4-(6-metoxipiridin-3-il)-cilohexil) pirrolidin-3-il)amino)-2-oxoetil)-3- (trifluorometil) benzamida |
AU2006204038A1 (en) | 2005-01-06 | 2006-07-13 | Merck & Co., Inc. | Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders |
CN100364643C (zh) * | 2006-05-11 | 2008-01-30 | 同济大学 | 一种从排气中吸附回收净化有机物的方法和装置 |
US7671062B2 (en) * | 2006-07-28 | 2010-03-02 | Bristol-Myers Squibb Company | Modulators of chemokine receptor activity, crystalline forms and process |
ES2555004T3 (es) | 2008-12-10 | 2015-12-28 | Janssen Pharmaceutica N.V. | Antagonistas 4-azetidinil-1-heteroaril ciclohexanol de CCR2 |
ES2539161T3 (es) | 2009-04-16 | 2015-06-26 | Janssen Pharmaceutica Nv | Antagonistas 4-azetidinil-1-heteroaril-ciclohexano de CCR2 |
CN102459227B (zh) | 2009-04-17 | 2014-08-20 | 詹森药业有限公司 | Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂 |
PT3091012T (pt) * | 2009-12-17 | 2018-06-27 | Centrexion Therapeutics Corp | Antagonistas do receptor ccr2 e suas utilizações |
US9040526B2 (en) | 2010-02-09 | 2015-05-26 | Bristol-Myers Squibb Company | Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity |
US8642622B2 (en) | 2010-06-16 | 2014-02-04 | Bristol-Myers Squibb Company | Piperidinyl compound as a modulator of chemokine receptor activity |
MY172862A (en) * | 2011-03-10 | 2019-12-13 | Daiichi Sankyo Co Ltd | Dispiropyrrolidine derivatives |
AU2016263579B2 (en) * | 2015-05-21 | 2020-12-03 | Chemocentryx, Inc. | CCR2 modulators |
-
2016
- 2016-05-19 AU AU2016263579A patent/AU2016263579B2/en active Active
- 2016-05-19 RS RS20220041A patent/RS62809B1/sr unknown
- 2016-05-19 WO PCT/US2016/033210 patent/WO2016187393A1/en active Application Filing
- 2016-05-19 DK DK16797279.3T patent/DK3297438T3/da active
- 2016-05-19 PL PL16797279T patent/PL3297438T3/pl unknown
- 2016-05-19 ES ES16797279T patent/ES2904252T3/es active Active
- 2016-05-19 MA MA042133A patent/MA42133A/fr unknown
- 2016-05-19 MX MX2017014375A patent/MX2017014375A/es unknown
- 2016-05-19 EP EP16797279.3A patent/EP3297438B1/en active Active
- 2016-05-19 CN CN201680029546.7A patent/CN108135168B/zh active Active
- 2016-05-19 LT LTEPPCT/US2016/033210T patent/LT3297438T/lt unknown
- 2016-05-19 BR BR112017024555A patent/BR112017024555A2/pt not_active Application Discontinuation
- 2016-05-19 CA CA2985194A patent/CA2985194A1/en active Pending
- 2016-05-19 KR KR1020177036757A patent/KR102622891B1/ko active IP Right Grant
- 2016-05-19 SI SI201631442T patent/SI3297438T1/sl unknown
- 2016-05-19 PT PT167972793T patent/PT3297438T/pt unknown
- 2016-05-19 HR HRP20220028TT patent/HRP20220028T1/hr unknown
- 2016-05-19 JP JP2017560247A patent/JP6841771B2/ja active Active
- 2016-05-19 NZ NZ737399A patent/NZ737399A/en unknown
- 2016-05-19 RU RU2017144651A patent/RU2726206C2/ru active
- 2016-05-19 US US15/158,713 patent/US9783540B2/en active Active
- 2016-05-19 HU HUE16797279A patent/HUE060376T2/hu unknown
- 2016-05-20 AR ARP160101482A patent/AR104720A1/es unknown
- 2016-05-20 TW TW105115844A patent/TWI733670B/zh active
-
2017
- 2017-08-31 US US15/692,811 patent/US10464934B2/en active Active
- 2017-11-07 IL IL255509A patent/IL255509B/en active IP Right Grant
- 2017-11-23 ZA ZA2017/07966A patent/ZA201707966B/en unknown
-
2019
- 2019-09-23 US US16/579,488 patent/US20200121688A1/en not_active Abandoned
-
2021
- 2021-06-24 US US17/357,427 patent/US20220153733A1/en active Pending
-
2022
- 2022-01-19 CY CY20221100047T patent/CY1124918T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201707966B (en) | Ccr2 modulators | |
HK1244652A1 (zh) | 可操縱微型內窺鏡 | |
GB201413018D0 (en) | Beyond 1A | |
PL3303291T3 (pl) | Modulatory ROR-gamma | |
PL3303290T3 (pl) | Modulatory ROR-gamma | |
PL3303293T3 (pl) | Modulatory ROR-gamma | |
DK3380145T3 (en) | Injektionsapparat | |
PL3319942T3 (pl) | MODULATORY ROR-GAMMA (RORγ) | |
IL266261A (en) | ror-gamma modulators | |
DK3324768T3 (en) | Tørdragt | |
AU361999S (en) | Ballustrade | |
GB201503400D0 (en) | Ink | |
DK3250312T3 (en) | Urea-metalnitrat-scr-system | |
GB201502316D0 (en) | Bitcon technology | |
IL253662A0 (en) | A method and apparatus for vacuum purification of silicon | |
DK3242882T3 (en) | Cgrp-antagonistpeptider | |
GB2544748B (en) | Microscaffold | |
GB201502073D0 (en) | HDEG technology | |
AU5516P (en) | LEP08 Lepidosperma squamatum | |
AU5511P (en) | PTK647 Epichloe coenophiala | |
AU366552S (en) | Nutblock | |
GB201522365D0 (en) | Concept abcd12 | |
GB201519328D0 (en) | Drydam | |
PL3365601T3 (pl) | Krematoria | |
GB201518520D0 (en) | Concept ABCD4 |